Key points are not available for this paper at this time.
Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%.Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO Merck) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/ Mvabea [Johnson 95%) shipped from the ICG stockpile have been repurposed for preventive vaccination of high-risk groups, compared with 6,570 (5%) used for outbreak response.Repurposing doses for preventive vaccination could be prioritized in the absence of Ebola outbreaks to prevent transmission and maximize the cost-efficiency and benefits of the stockpile.
Kallay et al. (Thu,) studied this question.